Evogene Valuation
| EVGN Stock | ILA 503.60 4.40 0.87% |
At this time, the firm appears to be overvalued. Evogene shows a prevailing Real Value of 459.86 per share. The current price of the firm is 503.6. Our model computes the value of Evogene from reviewing the firm fundamentals such as Shares Outstanding of 41.22 M, operating margin of (24.02) %, and Shares Owned By Insiders of 3.58 % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Evogene's price fluctuation is very steady at this time. Calculation of the real value of Evogene is based on 3 months time horizon. Increasing Evogene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Evogene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Evogene Stock. However, Evogene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 503.6 | Real 459.86 | Hype 503.6 | Naive 465.18 |
The real value of Evogene Stock, also known as its intrinsic value, is the underlying worth of Evogene Company, which is reflected in its stock price. It is based on Evogene's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Evogene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Evogene helps investors to forecast how Evogene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Evogene more accurately as focusing exclusively on Evogene's fundamentals will not take into account other important factors: Evogene Total Value Analysis
Evogene is currently forecasted to have takeover price of 8.8 M with market capitalization of 121.59 M, debt of 2.39 M, and cash on hands of 65.36 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Evogene fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.8 M | 121.59 M | 2.39 M | 65.36 M |
Evogene Investor Information
The company has price-to-book (P/B) ratio of 0.93. Some equities with similar Price to Book (P/B) outperform the market in the long run. Evogene recorded a loss per share of 0.72. The entity had not issued any dividends in recent years. The firm had 10:1 split on the 28th of July 2024. Based on the measurements of operating efficiency obtained from Evogene's historical financial statements, Evogene is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Evogene Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Evogene has an asset utilization ratio of 1.22 percent. This suggests that the Company is making 0.0122 for each dollar of assets. An increasing asset utilization means that Evogene is more efficient with each dollar of assets it utilizes for everyday operations.Evogene Ownership Allocation
Evogene holds a total of 41.22 Million outstanding shares. Evogene shows 3.58 percent of its outstanding shares held by insiders and 3.37 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Evogene Profitability Analysis
The company reported the revenue of 930 K. Net Loss for the year was (27.79 M) with profit before overhead, payroll, taxes, and interest of 163 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Evogene's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Evogene and how it compares across the competition.
About Evogene Valuation
The stock valuation mechanism determines Evogene's current worth on a weekly basis. Our valuation model uses a comparative analysis of Evogene. We calculate exposure to Evogene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Evogene's related companies.Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. EVOGENE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 131 people.
8 Steps to conduct Evogene's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Evogene's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Evogene's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Evogene's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Evogene's revenue streams: Identify Evogene's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Evogene's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Evogene's growth potential: Evaluate Evogene's management, business model, and growth potential.
- Determine Evogene's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Evogene's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Evogene Stock analysis
When running Evogene's price analysis, check to measure Evogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evogene is operating at the current time. Most of Evogene's value examination focuses on studying past and present price action to predict the probability of Evogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evogene's price. Additionally, you may evaluate how the addition of Evogene to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |